A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Required: EBV positive

Diagnosis of EBV+ disease

Cannot have received: investigational product

Within 4 weeks or 5 half-lives (whichever is shorter) for any investigational product

Cannot have received: chemotherapy

Within 4 weeks or 5 half-lives (whichever is shorter) for any...chemotherapy (systemic or intrathecal)

Cannot have received: targeted small molecule therapy

Within 4 weeks or 5 half-lives (whichever is shorter) for any...targeted small molecule therapy

Cannot have received: antibody/biologic therapy

Exception: prior anti-CD20 antibody use is permitted within the washout period if a subsequent disease response assessment indicates disease progression

Within 4 weeks or 5 half-lives (whichever is shorter) for any...antibody/biologic therapy

Cannot have received: cellular therapies (CAR-T, donor lymphocyte infusion, other CTLs or virus-specific T-cells)

Within 8 weeks: prior tabelecleucel (> 8 weeks prior to enrollment) is permitted if response was obtained or if usual protocol-directed therapeutic options were not exhausted, for cellular therapies (chimeric antigen receptor therapies directed at T-cells or T-cell subsets, donor lymphocyte infusion, other CTLs or virus-specific T-cells); and/or therapies which could impact tabelecleucel function (anti-thymocyte globulin, alemtuzumab)

Cannot have received: anti-thymocyte globulin

therapies which could impact tabelecleucel function (anti-thymocyte globulin, alemtuzumab)

Cannot have received: alemtuzumab

therapies which could impact tabelecleucel function (anti-thymocyte globulin, alemtuzumab)

Cannot have received: EBV-CTLs

Exception: tabelecleucel as above

Any prior treatment with EBV-CTLs with the exception of tabelecleucel as above